Developer docs
API playgroundTry for free, no card

Search company profiles

Avalon Pharma

Full company profile

uuid0000b3i

Namestring
Avalon Pharma
Legal namestring
Avalon Pharma
Company typeenum
Public
Founded yearint
1998
Descriptiontext

Avalon Pharma is a Saudi Arabian pharmaceutical manufacturer founded in 1998 and headquartered in Riyadh, publicly listed on the Saudi Exchange (Tadawul) under ticker 4016. The company develops and manufactures branded pharmaceutical-based health and beauty products, with a stated emphasis on eco-friendly formulations and sustainable product development dating to its founding. Its product portfolio spans prescription medicines and consumer health/beauty offerings built on scientifically researched formulations with clinically-proven ingredients. The company is led by Chairman Ahmad Tabbaa and President & CEO Maher Ghannam. Avalon distributes through traditional pharmaceutical wholesale channels serving pharmacies and healthcare providers in Saudi Arabia and the wider MENA region, operating a sales-led go-to-market model targeting both healthcare consumers and patients.

Avalon reported revenue of SAR 130 million with 34% year-over-year growth and net profit of SAR 27 million with 39% growth, implying a net margin of approximately 21%. The business is financed in part through Shariah-compliant debt — SAR 70 million from Emirates NBD in July 2024 and approximately SAR 54 million from The Saudi Investment Bank in August 2025 — supporting operational expansion. In February 2026, Avalon entered a strategically significant licensing and commercialization agreement with Chinese biotech Bio-Thera Solutions for BAT3306, a proposed pembrolizumab (Keytruda) biosimilar, covering Saudi Arabia and the broader MENA region; Bio-Thera retains development, manufacturing, and supply responsibility while Avalon leads commercialization in licensed territories. This deal represents a material move into specialty oncology biosimilars beyond its traditional generic and consumer health portfolio.

Avalon has earned external recognition including Great Place to Work certification in 2025 and 2026, and an Argaam Best CEO award for 2025, alongside CSR engagements such as a World No Tobacco Day awareness initiative with NAQA Association. The company's competitive positioning rests on regulatory-licensed manufacturing, an established regional distribution footprint, brand heritage built since 1998, and an eco-friendly differentiation narrative — though evidence of substantive AI/ML or proprietary technology depth is limited.

Short descriptiontext

Avalon Pharma is a Riyadh-headquartered, publicly listed Saudi pharmaceutical manufacturer founded in 1998, producing branded prescription medicines and consumer health/beauty products for distribution through wholesale channels across Saudi Arabia and the broader MENA region.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersRiyadh, Saudi Arabia
HQ citystring
Riyadh
HQ countrystring
Saudi Arabia
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, generic medicines, health beauty products, prescription drugs, biosimilar distribution
Industry3 codes
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
SECONDARYHLAIABAJ
Generic ANDA/Regulatory Affairs & Submissions
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Medicinal and Botanical Manufacturing325411
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Medicinal Chemicals & Botanical Products2833
Product category
Pharmaceutical Manufacturing
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical product sales
TypeOne Time License
Description

Avalon Pharma generates revenue through the manufacture and sale of pharmaceutical products and health and beauty products. The company develops branded products rooted in scientific research with clinically-proven ingredients.

avalonpharmaceutical.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Avalon Pharma manufactures and distributes branded pharmaceutical-based health and beauty products as well as generic prescription medicines, developed through scientific research with clinically-proven ingredients and a commitment to eco-friendly, sustainable formulations. The portfolio is rooted in rigorous testing and trials to ensure quality, and the company is expanding its therapeutic footprint through biosimilar licensing partnerships such as the Bio-Thera Solutions BAT3306 (pembrolizumab biosimilar) deal covering Saudi Arabia and the MENA region.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Avalon Pharma offers a portfolio of pharmaceutical-based health and beauty products. The company operates across multiple segments including product development, manufacturing, and business development. Their product range includes both pharmaceutical treatments and consumer health/beauty offerings, though specific product brand names are not detailed in the available source data. The company also recently entered into a commercialization and license agreement with Bio-Thera Solutions for BAT3306, a proposed biosimilar to Keytruda (pembrolizumab), covering Saudi Arabia and the wider MENA region.

Product and service3 records
1Avalon Pharma branded health and beauty products
CategoryHealth and personal care
Description

A portfolio of pharmaceutical-based health and beauty brands developed with scientifically researched, clinically-proven ingredients and eco-friendly formulations, designed to address health conditions, wellness needs, and beauty concerns for end consumers.

2Avalon Pharma generic prescription medicines
CategoryPharmaceuticals
Description

Generic prescription pharmaceutical products manufactured by Avalon Pharma, distributed through wholesale and pharmacy channels in Saudi Arabia and the MENA region to provide effective pharmacological treatments.

3BAT3306 (pembrolizumab biosimilar)
CategoryBiosimilars
Description

A proposed biosimilar to Keytruda (pembrolizumab) that Avalon Pharma will commercialize under a license from Bio-Thera Solutions across Saudi Arabia and the wider MENA region for oncology indications.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-09
Description

Chinese biotech Bio-Thera Solutions signed commercialization and license agreements with Avalon Pharma for BAT3306, a proposed biosimilar to Keytruda (pembrolizumab), covering Saudi Arabia and the wider Middle East and North Africa region. Bio-Thera retains responsibility for development, manufacturing, and supply while Avalon pursues regulatory approvals and leads commercialization across licensed territories.

TypeOthers
Description

Avalon Pharma partnered with NAQA Association to launch an awareness initiative on World No Tobacco Day, demonstrating corporate social responsibility engagement.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Saudi Arabia's largest listed pharmaceutical manufacturer producing branded generics and OTC products — directly comparable to Avalon in therapeutic focus, manufacturing footprint, and Tadawul listing.

TypeDirect peer
Description

Leading Saudi generic pharma manufacturer with MENA presence — closely comparable product portfolio (branded generics, OTC, health & beauty adjacencies) and target customers (pharmacies and healthcare providers).

3Julphar (Gulf Pharmaceutical Industries)
TypeDirect peer
Description

UAE-headquartered generic and specialty pharma manufacturer with regional MENA distribution — directly comparable as a regional pharma manufacturer operating across the same geographies and therapeutic categories.

TypeBroad incumbent
Description

Jordan-anchored multinational generics and specialty pharma with deep MENA presence — broader portfolio and global scale but directly overlapping product categories and regional customer base as Avalon.

5Pharmax Pharmaceuticals
TypeDirect peer
Description

UAE-based generic and specialty pharma manufacturer with regional MENA distribution — directly comparable branded generics business model and geographic customer footprint.

TypeDirect peer
Description

One of the largest generic pharma manufacturers in the MENA region — directly comparable as a regional generics manufacturer serving similar healthcare provider and pharmacy channels.

TypeEmerging player
Description

China-based biosimilar developer and Avalon's commercialization partner for BAT3306 (Keytruda biosimilar) — comparable as a biosimilar-focused biotech targeting emerging markets, with overlapping oncology pipeline intent.

TypeBroad incumbent
Description

Global generics major with active presence in MENA through partnerships — broader scale and geographic reach but overlapping generic pharma product category and emerging-market commercialization model.

9Al-Takween (National Medical Products Co.)
TypeRegional player
Description

Saudi pharma manufacturer focused on health, beauty, and personal care pharmaceutical products — comparable in the consumer health and beauty segment Avalon also targets.

TypeRegional player
Description

Saudi-domiciled pharmaceutical manufacturer referenced alongside Avalon in shareholder communications — regional peer with overlapping manufacturing and distribution profile in Saudi Arabia.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Avalon Pharma

Pharmaceutical Manufacturingavalonpharmaceutical.com

Avalon Pharma is a Riyadh-headquartered, publicly listed Saudi pharmaceutical manufacturer founded in 1998, producing branded prescription medicines and consumer health/beauty products for distribution through wholesale channels across Saudi Arabia and the broader MENA region.

What Avalon Pharma does

Avalon Pharma is a Saudi Arabian pharmaceutical manufacturer founded in 1998 and headquartered in Riyadh, publicly listed on the Saudi Exchange (Tadawul) under ticker 4016. The company develops and manufactures branded pharmaceutical-based health and beauty products, with a stated emphasis on eco-friendly formulations and sustainable product development dating to its founding. Its product portfolio spans prescription medicines and consumer health/beauty offerings built on scientifically researched formulations with clinically-proven ingredients. The company is led by Chairman Ahmad Tabbaa and President & CEO Maher Ghannam. Avalon distributes through traditional pharmaceutical wholesale channels serving pharmacies and healthcare providers in Saudi Arabia and the wider MENA region, operating a sales-led go-to-market model targeting both healthcare consumers and patients.

Avalon reported revenue of SAR 130 million with 34% year-over-year growth and net profit of SAR 27 million with 39% growth, implying a net margin of approximately 21%. The business is financed in part through Shariah-compliant debt — SAR 70 million from Emirates NBD in July 2024 and approximately SAR 54 million from The Saudi Investment Bank in August 2025 — supporting operational expansion. In February 2026, Avalon entered a strategically significant licensing and commercialization agreement with Chinese biotech Bio-Thera Solutions for BAT3306, a proposed pembrolizumab (Keytruda) biosimilar, covering Saudi Arabia and the broader MENA region; Bio-Thera retains development, manufacturing, and supply responsibility while Avalon leads commercialization in licensed territories. This deal represents a material move into specialty oncology biosimilars beyond its traditional generic and consumer health portfolio.

Avalon has earned external recognition including Great Place to Work certification in 2025 and 2026, and an Argaam Best CEO award for 2025, alongside CSR engagements such as a World No Tobacco Day awareness initiative with NAQA Association. The company's competitive positioning rests on regulatory-licensed manufacturing, an established regional distribution footprint, brand heritage built since 1998, and an eco-friendly differentiation narrative — though evidence of substantive AI/ML or proprietary technology depth is limited.

Avalon Pharma firmographics

Firmographics
Name
Avalon Pharma
Legal name
Avalon Pharma
Website
https://avalonpharmaceutical.com
Company type
Public
Founded year
1998
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Avalon Pharma is a Riyadh-headquartered, publicly listed Saudi pharmaceutical manufacturer founded in 1998, producing branded prescription medicines and consumer health/beauty products for distribution through wholesale channels across Saudi Arabia and the broader MENA region.
Ownership category
akta.pro rank

Avalon Pharma industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
SECONDARYHLAIABAJ
Generic ANDA/Regulatory Affairs & Submissions

Keywords

  • Pharmaceutical manufacturing
  • Generic medicines
  • Health beauty products
  • Prescription drugs
  • Biosimilar distribution

Where Avalon Pharma is headquartered

Location

Headquarters

HQ city
Riyadh
HQ country
Saudi Arabia
HQ region
Middle East

Offices1 record

Markets served

Avalon Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical product sales: Avalon Pharma generates revenue through the manufacture and sale of pharmaceutical products and health and beauty products. The company develops branded products rooted in scientific research with clinically-proven ingredients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Avalon Pharma product offering

Product offering

Core offering

Avalon Pharma manufactures and distributes branded pharmaceutical-based health and beauty products as well as generic prescription medicines, developed through scientific research with clinically-proven ingredients and a commitment to eco-friendly, sustainable formulations. The portfolio is rooted in rigorous testing and trials to ensure quality, and the company is expanding its therapeutic footprint through biosimilar licensing partnerships such as the Bio-Thera Solutions BAT3306 (pembrolizumab biosimilar) deal covering Saudi Arabia and the MENA region.

Product overview

Avalon Pharma offers a portfolio of pharmaceutical-based health and beauty products. The company operates across multiple segments including product development, manufacturing, and business development. Their product range includes both pharmaceutical treatments and consumer health/beauty offerings, though specific product brand names are not detailed in the available source data. The company also recently entered into a commercialization and license agreement with Bio-Thera Solutions for BAT3306, a proposed biosimilar to Keytruda (pembrolizumab), covering Saudi Arabia and the wider MENA region.

Differentiator

Problem solved

Functional benefit

Products and services

  • Avalon Pharma branded health and beauty products A portfolio of pharmaceutical-based health and beauty brands developed with scientifically researched, clinically-proven ingredients and eco-friendly formulations, designed to address health conditions, wellness needs, and beauty concerns for end consumers.
  • Avalon Pharma generic prescription medicines Generic prescription pharmaceutical products manufactured by Avalon Pharma, distributed through wholesale and pharmacy channels in Saudi Arabia and the MENA region to provide effective pharmacological treatments.
  • BAT3306 (pembrolizumab biosimilar) A proposed biosimilar to Keytruda (pembrolizumab) that Avalon Pharma will commercialize under a license from Bio-Thera Solutions across Saudi Arabia and the wider MENA region for oncology indications.

Companies that use Avalon Pharma

Customer profile

Segments1 record

Ideal customer profiles3 records

Avalon Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Avalon Pharma partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Bio-Thera SolutionscoreStrategic or Co-development Partner · 9 February 2026Chinese biotech Bio-Thera Solutions signed commercialization and license agreements with Avalon Pharma for BAT3306, a proposed biosimilar to Keytruda (pembrolizumab), covering Saudi Arabia and the wider Middle East and North Africa region. Bio-Thera retains responsibility for development, manufacturing, and supply while Avalon pursues regulatory approvals and leads commercialization across licensed territories.
  • NAQA AssociationOthersAvalon Pharma partnered with NAQA Association to launch an awareness initiative on World No Tobacco Day, demonstrating corporate social responsibility engagement.

Scale indicators4 records

Recent moves3 records

Expansion highlights4 records

Avalon Pharma competitors and assessment

Company assessment

Direct peers

  • Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO): Saudi Arabia's largest listed pharmaceutical manufacturer producing branded generics and OTC products — directly comparable to Avalon in therapeutic focus, manufacturing footprint, and Tadawul listing.
  • Tabuk Pharmaceuticals: Leading Saudi generic pharma manufacturer with MENA presence — closely comparable product portfolio (branded generics, OTC, health & beauty adjacencies) and target customers (pharmacies and healthcare providers).
  • Julphar (Gulf Pharmaceutical Industries): UAE-headquartered generic and specialty pharma manufacturer with regional MENA distribution — directly comparable as a regional pharma manufacturer operating across the same geographies and therapeutic categories.
  • Pharmax Pharmaceuticals: UAE-based generic and specialty pharma manufacturer with regional MENA distribution — directly comparable branded generics business model and geographic customer footprint.
  • EIPICO (Egyptian International Pharmaceutical Industries Company): One of the largest generic pharma manufacturers in the MENA region — directly comparable as a regional generics manufacturer serving similar healthcare provider and pharmacy channels.

Broad incumbents

  • Hikma Pharmaceuticals: Jordan-anchored multinational generics and specialty pharma with deep MENA presence — broader portfolio and global scale but directly overlapping product categories and regional customer base as Avalon.
  • Cipla: Global generics major with active presence in MENA through partnerships — broader scale and geographic reach but overlapping generic pharma product category and emerging-market commercialization model.

Emerging players

  • Bio-Thera Solutions: China-based biosimilar developer and Avalon's commercialization partner for BAT3306 (Keytruda biosimilar) — comparable as a biosimilar-focused biotech targeting emerging markets, with overlapping oncology pipeline intent.

Regional players

  • Al-Takween (National Medical Products Co.): Saudi pharma manufacturer focused on health, beauty, and personal care pharmaceutical products — comparable in the consumer health and beauty segment Avalon also targets.
  • Middle East Pharmaceutical Industries Co. (Avalon Pharma referenced shareholder notice): Saudi-domiciled pharmaceutical manufacturer referenced alongside Avalon in shareholder communications — regional peer with overlapping manufacturing and distribution profile in Saudi Arabia.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Avalon Pharma social profiles

Digital presence

Avalon Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Avalon Pharma leadership team

Management profile

Number of profiles

Profiles3 records

Avalon Pharma funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Avalon Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avalon Pharma

What does Avalon Pharma do?

Avalon Pharma manufactures and distributes branded pharmaceutical-based health and beauty products as well as generic prescription medicines, developed through scientific research with clinically-proven ingredients and a commitment to eco-friendly, sustainable formulations. The portfolio is rooted in rigorous testing and trials to ensure quality, and the company is expanding its therapeutic footprint through biosimilar licensing partnerships such as the Bio-Thera Solutions BAT3306 (pembrolizumab biosimilar) deal covering Saudi Arabia and the MENA region.

Is Avalon Pharma a public or private company?

Avalon Pharma is a public company. It is classified as public and is currently operating.

When was Avalon Pharma founded?

Avalon Pharma was founded in 1998. It employs 501 to 1,000 people.

Where is Avalon Pharma based?

Avalon Pharma is headquartered in Riyadh, Saudi Arabia, in the Middle East region.

How does Avalon Pharma make money?

One revenue line is on record: pharmaceutical product sales.

Who are Avalon Pharma's main competitors?

Direct peers on record are Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO), Tabuk Pharmaceuticals, Julphar (Gulf Pharmaceutical Industries), Pharmax Pharmaceuticals and EIPICO (Egyptian International Pharmaceutical Industries Company). Broad incumbents are Hikma Pharmaceuticals and Cipla. Bio-Thera Solutions is listed as an emerging player. Regional players are Al-Takween (National Medical Products Co.) and Middle East Pharmaceutical Industries Co. (Avalon Pharma referenced shareholder notice).

Does Avalon Pharma have an API?

No public API is recorded for Avalon Pharma.

What industry is Avalon Pharma in?

Avalon Pharma's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAGAMAD, Specialty Pharma & Biologics Distribution (GDP-compliant). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ArgaamAvalon’s Generic Mounjaro Is Not Yet Saudi-MadeAvalon Pharma licensed a generic tirzepatide (Mounjaro) to OneSource Specialty Pharma, with no launch date. The deal could generate at least SAR800 million in five years, but Saudi production is not yet confirmed. Launch depends on patent expirations and manufacturing transfer.ArgaamAvalon Pharma licenses drug for Saudi Arabia, other marketsAvalon Pharma signed an exclusive licensing agreement with OneSource Specialty Pharma to register and market Tirzepatide in Saudi Arabia and other MENA markets. The 10-year deal, worth less than 5% of Avalon's revenue, expects cumulative revenue of at least SAR 800 million in the first five years.Simply Wall StShould Income Investors Look At Middle East Pharmaceutical Industries Company (TADAWUL:4016) Before Its Ex-Dividend?Middle East Pharmaceutical Industries is set to trade ex-dividend in four days, with the dividend of ر.س0.80 per share paid on September 15. The company paid ر.س1.38 last year, giving a trailing yield of 2.1% on ر.س64.75, and paid out 24% of profit but 229% of free cash flow. Earnings per share rose 8.3% annually over five years, with dividends up about 27% yearly.Mubasher InfoAvalon Pharma extends SAR 50m credit facility deal with Alinma BankAvalon Pharma renewed its Sharia-compliant banking facility with Alinma Bank on 19 August for SAR 50 million, with a one-year term. The company provided a promissory note as a guarantee, and the funds will support working capital and capital expenditures. No related parties are involved in the transaction.SahmcapitalAvalon Pharma Secures Exclusive Dupilumab Biosimilar Rights in MENAAvalon Pharma secured exclusive rights to commercialize a Dupilumab biosimilar in the MENA region through a strategic agreement with Bio-Thera Solutions Inc. The 15-year renewable contract, valued at less than 5% of Avalon Pharma's annual revenues, includes future localization manufacturing rights and projects cumulative revenues of at least SAR 400 million within seven years of the anticipated 2031 launch.AInvestAvalon Pharma: contract grants co the exclusive license rights to register and commercialize “Dupilumab” across KSA & MENA marketsAvalon Pharma has secured an exclusive license agreement to register and commercialize the drug Dupilumab in Saudi Arabia and the broader Middle East and North Africa (MENA) region. This contract grants the company sole rights to manage the product's market entry and sales within these specific territories.ArgaamAvalon Pharma signs agreement to commercialize Dupilumab biosimilarAvalon Pharma has signed an agreement with Bio-Thera Solutions to commercialize BAT2406, a biosimilar to Dupixent, in Saudi Arabia and the broader MENA region. Under the deal, Avalon Pharma holds exclusive rights for registration and commercialization while Bio-Thera retains responsibility for development and manufacturing. The contract value is reported to be less than 5% of Avalon Pharma's annual revenue.AInvestAvalon Pharma - H1 dividend per share SAR 0.80Avalon Pharma announced a dividend of SAR 0.80 per share for the first half of 2026. The announcement was made on Monday, August 10, 2026. No additional context regarding the company's financial performance or strategic rationale for the dividend was provided in the article.ArgaamTASI reports 5 negotiated deals worth SAR 17.6MThe Saudi Exchange (Tadawul) recorded five negotiated share deals worth SAR 17.6 million on June 16, involving shares of SAL, Astra, Avalon Pharma, and Arab Sea. The largest deal was for SAL shares valued at SAR 5.85 million, followed by Astra at SAR 3.43 million and Avalon Pharma at SAR 1.43 million. Negotiated deals are executed when buyers and sellers agree on a specific price under Tadawul supervision, but do not impact market indices or last deal prices.The Pharma LetterBio-Thera, Avalon strike MENA deal for proposed Keytruda biosimilarChinese biotech Bio-Thera Solutions has signed commercialization and license agreements with Saudi drugmaker Avalon Pharma for BAT3306, a proposed biosimilar to Keytruda (pembrolizumab), covering Saudi Arabia and the wider Middle East and North Africa region. Under the deal, Bio-Thera retains responsibility for development, manufacturing, and supply while Avalon will pursue regulatory approvals and lead commercialization across the licensed territories. The partners framed the agreement as a step toward widening access to immuno-oncology medicines in the MENA region.